PharmEasy’s INR 3,500 Cr Rights Issue Oversubscribed

“We raised INR 3,500 Cr and there was more demand which we had to politely reject.” wrote cofounder Dhaval Shah on LinkedIn. The goal of the rights issue was to repay a large portion of its debt to Goldman Sachs. PharmEasy parent, API Holdings clocked EBIDTA of INR 60 Cr in the first 6 months of FY24, Shah added.